Table 3.
Association of macrolide therapy with 90-day mortality and with MERS-CoV RNA clearance in critically ill patients with Middle East Respiratory Syndrome (MERS).
| Day-90 mortality |
MERS-CoV RNA clearancea |
|||||
|---|---|---|---|---|---|---|
| Variables | Logistic regression |
Cox proportional hazard model |
||||
| n | OR (95% CI) |
P-value | n | HR (95% CI) |
P-value | |
| Macrolides vs no macrolides (ref) | 268 | 0.84 (0.47, 1.51) |
0.56 | 137 | 0.88 (0.47, 1.64) |
0.68 |
| Macrolides vs no macrolides (ref) among survivors | 55 | 0.75 (0.35, 1.62) |
0.46 | |||
a
Clearance of MERS-CoV rRT-PCR was calculated on patients who had at least one follow-up rRT-PCR test in the ICU from the date of ICU admission, and censored by the date of last test or death whichever comes first. For the cox proportional analysis: Event – cleared, Censored – not cleared – Discharged Alive, Palliative Discharge, Still In Hospital, Transferred To Other Facility.